(CercleFinance.com) – IntegraGen shares jumped on the Paris Stock Exchange on Friday, the specialist in cancer genomics and genetic diseases having announced new double-digit growth in its activity in 2021.
The company – which carries out genomic analyzes for academic and private laboratories – indicates that its annual turnover increased by 21% to amount to 10.9 million euros.
This is the first time that the company has exceeded the threshold of ten million euros in revenue.
This growth was generated in particular by income from the shared microbiology platform operated for the Institut Pasteur, which was heavily used in the context of the Covid-19 virus pandemic.
The company explains that the sequencing needs of new variants have resulted in a doubling of volumes compared to 2020.
At the end of 2021, its cash amounted to 4.8 million euros, compared to 5.1 million euros at the end of 2020.
IntegraGen also confirms its growth prospects on the basis of an increasing order book and the multi-year contracts already in place.
At 11:40 a.m., the stock rose by more than 30%, marking the biggest rise in the Paris market.